International Journal of Scientific Research and Engineering Development-– Volume 8 Issue 5, Sep-Oct 2025
Available at www.ijsred.com

RESEARCH ARTICLE OPEN ACCESS

A Systematic Review of Anticancer Activities: Mechanisms, Efficacy, and Challenges

Rohit Kumar Pandey[1], Rishi raj[1], Pankaj Kumar[1], Nakul Gupta[1], Pushkar Kumar Ray*[1]
[1]IIMT College of Pharmacy. A.P.J Abdul Kalam Technical University (AKTU), Knowledge Park-3, Greater Noida, Gautam Budha Nagar-201310, U.P, India;

*Corresponding Author: Pushkar Kumar Ray
E. mail: pushkarkumarray34@gmail.com

----------**********----------

ABSTRACT:
Cancer remains a major global health challenge due to its increasing incidence, mortality, and complex biology. Traditional chemotherapy has long served as the primary treatment, but its non-selective cytotoxicity often results in significant toxicity. Advances in molecular oncology have enabled the development of targeted therapies, hormonal treatments, and immunotherapies that selectively disrupt cancer-specific pathways, improve survival, and reduce adverse effects. Preclinical evaluation using in vitro models, 3D cultures, and animal studies supports drug discovery, although many agents fail to translate clinically due to tumor heterogeneity and microenvironmental barriers. Drug delivery challenges including poor bioavailability and off-target effects limit therapeutic outcomes, prompting the development of nanocarriers and stimuli-responsive systems. Natural products continue to provide promising anticancer leads. Despite progress, resistance, toxicity, and limited specificity remain obstacles. Future success depends on precision medicine, biomarker-guided treatment, combination strategies, and advanced delivery platforms to achieve safer and more effective cancer therapy.

Keywords: Cancer, Worldwide, Anticancer Activities, Anticancer efficacy, Mechanism of action.

----------**********----------

1. INTRODUCTION

1.1. The Global Cancer Burden: Present statistics on cancer incidence and mortality worldwide.

Cancer remains one of the leading causes of death globally and represents a major challenge for public health systems. According to the most recent estimates, approximately 20 million new cases of cancer and nearly 10 million cancer-related deaths occurred worldwide in 2022.[1] This growing burden reflects a combination of factors, including population growth, aging, and changes in lifestyle and environmental exposures.[2] The distribution of cancer incidence and mortality varies significantly across regions. While high-income countries report a higher incidence due to advanced diagnostic facilities and longer life expectancy, low- and middle-income countries bear a disproportionate share of mortality, largely because of delayed diagnosis, limited access to treatment, and inadequate healthcare infrastructure. Lung, breast, colorectal, prostate, and stomach cancers collectively account for nearly half of all new cases, with lung cancer remaining the leading cause of cancer-related deaths. Projections indicate that the global cancer burden will continue to rise, with annual new cases expected to exceed 35 million by 2050.[3] This anticipated increase underscores the urgent need for comprehensive prevention strategies, early detection programs, and equitable access to effective treatment. Addressing modifiable risk factors such as tobacco use, obesity, alcohol consumption, and infection-related cancers (e.g., human papillomavirus and hepatitis B/C) is central to reducing the future impact of cancer worldwide.[4]

1.2. The Evolution of Cancer Therapy: Briefly journey from conventional chemotherapy to targeted therapy and immunotherapy. Highlight the paradigm shift towards precision medicine.

The treatment of cancer has undergone a remarkable transformation over the past several decades. In the mid-20th century, conventional chemotherapy emerged as the mainstay of therapy, using cytotoxic agents that indiscriminately

 ©IJSRED: All Rights are Reserved

targeted rapidly dividing cells.[5] While these drugs were effective in shrinking tumors, they were often associated with significant toxicity and limited specificity, resulting in damage to normal tissues and reduced quality of life. [6,7]

The introduction of molecular biology and cancer genetics in the late 20th century paved the way for targeted therapies. Unlike traditional chemotherapeutics, targeted agents act on specific molecular pathways essential for tumor growth and survival. [8,9] Examples include tyrosine kinase inhibitors and monoclonal antibodies directed against growth factor receptors. These treatments represented a major shift, offering improved efficacy and reduced toxicity compared to earlier regimens. [10-13] The next major milestone was the development of cancer immunotherapy, which harnesses the body's own immune system to fight malignancies.[14] Immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 blockers, as well as adoptive T-cell therapies, have demonstrated durable responses in cancers previously considered untreatable.[15-17 Together, these advances have ushered in the era of precision medicine, where therapeutic strategies are increasingly tailored to the genetic and molecular profile of each patient's tumor.[18-20] This paradigm shift emphasizes individualized treatment planning, integrating genomic testing, biomarker identification, and novel drug development.[20-23] The transition from nonspecific cytotoxic therapy to precision-guided interventions reflects one of the most significant achievements in modern oncology.[24-26]

2. METHODOLOGY (THE "SYSTEMATIC" PART)

2.1. Search Strategy: Detail the systematic process.

To create a strong and reproducible seek method for an anti-cancer methodology, a scientific system is used to pick out relevant studies.[27] The technique is frequently guided by way of frameworks which include the % version (population, Intervention, assessment, and final results) and documented in line with favored Reporting items for Systematic opinions and Meta-Analyses (PRISMA) tips.[28-30] This systematic search method usually includes the subsequent steps:

2.1. Formulate a focused research query

A clean, properly-described question guides the entire search method. For anti-cancer methodology, a percent framework is typically used:

populace (P): The form of most cancers, which includes "non-small mobile lung cancer" or "breast cancer with HER2-superb reputation".

Intervention (I): The precise anti-most cancers methodology being investigated, including "immunotherapy with PD-1 inhibitors".

comparison (C): The alternative or general remedy, such as "widespread cytotoxic chemotherapy" or "no treatment".

outcome (O): The outcomes being measured, consisting of "tumor size reduction," "progression-loose survival," or "damaging activities". [30-33]

2.2 Perceive and accumulate search terms

broaden a complete list of key phrases and controlled vocabulary (e.g., medical concern Headings or MeSH terms in PubMed) for each aspect of the % query. instance keyword accumulating for an anti-most cancers methodology: most cancers: cancer, neoplasm, carcinoma, malignancy, oncology. Immunotherapy: immunotherapy, immune checkpoint inhibitor, PD-1 inhibitor, PD-L1 inhibitor. medical trial design: randomized managed trial, clinical trial, examine. [34-36]

2.3 Select databases and information sources

To avoid bias, the search should cowl a couple of electronic databases and other resources of data, together with "grey literature" (unpublished studies). For anti-cancer method, the following sources are commonly searched: Bibliographic databases: MEDLINE (through PubMed): A number one database for existence sciences and biomedical statistics. Embase: A biomedical and pharmacological database, with broader coverage of ecu journals. Web of technology or Scopus: comprehensive, interdisciplinary databases that also enable quotation monitoring. medical trial registries: ClinicalTrials.gov: For ongoing and completed studies. global prospective register of Systematic evaluations (PROSPERO): To sign up and locate present systematic evaluate protocols.

 ©IJSRED: All Rights are Reserved

grey literature: convention complaints: To find current and unpublished research. Regulatory business enterprise web sites: which includes the FDA or EMA, for drug approval information four compose and run search strategies the use of Boolean operators (AND, OR, now not), truncation symbols (*), and proximity looking, construct a search string for every database. the hunt string have to be adapted for the specific controlled vocabulary and syntax regulations of each database. [37,38]

Boolean operators:

OR: Connects synonyms and associated terms to increase the hunt (e.g., cancer OR neoplasm).

AND: Combines ideas to narrow the hunt (e.g., most cancers AND immunotherapy).

Truncation: using an asterisk (*) lets in for a couple of endings of a root phrase (e.g., immuno-therap will locate immunotherapy, immunotherapies, and healing).[39,40]

2.4. Study Selection and Data Extraction:

A PRISMA waft diagram does not describe the anti-cancer process itself, however as an alternative illustrates the method of identifying and deciding on research for a scientific overview or meta-analysis on anti-cancer treatments or treatments.[41] The diagram commonly indicates the preliminary quantity of statistics identified from various databases, the removal of duplicates, the screening of titles and abstracts, the whole textual content evaluation for eligibility, and finally, the quantity of research covered inside the overview. here's a breakdown of the everyday degrees in a PRISMA glide diagram as it applies to gaining knowledge of anti-cancer approaches: identity: **Databases**: begins with the overall range of statistics (studies) identified from systematic database searches (e.g., PubMed, Scopus).[42] different resources: includes extra information found thru other methods, such as screening reference lists or contacting professionals. **Screening:** duplicate **elimination:** a specific range of replica information are eliminated after initial database searches. name/summary Screening: The last information are then screened based totally on titles and abstracts to exclude beside the point research.[43] **Eligibility:** complete-text Retrieval: studies deemed probably applicable are retrieved as fulltextual content articles. full-textual content Eligibility: the full-textual content articles are assessed against predefined inclusion and exclusion standards to determine their eligibility for the assessment. [44,45]

Inclusion: final studies: The final quantity of studies that meet all of the eligibility standards are covered inside the systematic assessment or metaevaluation. reasons for Exclusion: The diagram might also specify the variety of studies excluded at the full-text degree and the reasons for his or her exclusion. instance situation: imagine you are discovering the effectiveness of natural compounds in preventing cancer. A PRISMA float diagram could visually display: Specify the data extracted: author, year, study type, cancer type, agent studied, mechanism, key efficacy findings, and reported challenges.[46] A consumer has asked for a precis of extracted data, however has no longer provided a particular take a look at or article. consequently, it is not feasible to provide concrete information for a particular case. the subsequent is an outline of the sorts of facts which are usually extracted, based totally on satisfactory practices for systematic reviews in fields consisting of most cancers research. statistics extraction fields creator: The names of the look at's main investigators.[47] yr: The yr of the observe's booklet. examine type: This describes the studies method used (e.g., randomized controlled trial, case-manage look at, systematic assessment, meta-analysis). cancer type: The precise type(s) of most cancers investigated inside the look at Agent studied: The therapeutic agent, intervention, or drug being investigated (e.g., a particular chemotherapy drug, a herbal compound like anethole, or a transport gadget). Mechanism: The underlying organic system by using which the agent produces its impact. In most cancers research, this will involve mechanisms like inducing apoptosis inhibiting tumour increase or concentrated on particular molecular pathways.[48] Key efficacy findings: A precis of the observer's essential outcomes regarding the agent's effectiveness, which can also encompass survival costs, tumour reaction, or enhancements in a specific outcome. said demanding situations: Any barriers encountered at some point of the have a look at, consisting of treatment resistance, destructive aspect outcomes, or methodological issues.[49,50]

 ©IJSRED: All Rights are Reserved

3. CLASSIFICATION AND MECHANISMS OF ANTICANCER AGENTS

Anticancer sellers are widely categorised into traditional chemotherapies and more recent, targeted treatment options based totally on their mechanisms of action. traditional dealers normally target hastily dividing cells with the aid of damaging DNA or disrupting mobile strategies, whereas present day approaches goal for unique vulnerabilities in most cancers cells or increase the immune device.[51] category of anticancer tablets: an replace with FDA- and ... **classification and mechanisms**

DNA-unfavourable dealers those are non-precise and act immediately or not directly to damage the DNA of most cancers cells, which can be extra prone because of their high replication fee. Alkylating sellers: form covalent bonds with DNA, growing move-links that save you DNA replication and cause apoptosis. Examples: Cyclophosphamide, cisplatin, and carboplatin.

Cytotoxic antibiotics: intervene with DNA characteristic through diverse mechanisms. Doxorubicin works via intercalating (putting itself) into DNA and inhibiting topoisomerase II, an enzyme essential for DNA replication.[52]

Bleomycin degrades pre-shaped DNA by generating unfastened radicals. Topoisomerase inhibitors: entice topoisomerase enzymes on DNA, causing strand breaks that intervene with replication and transcription.[53]

Examples: Etoposide and topotecan: Antimetabolites those drugs mimic natural molecules needed for DNA and RNA synthesis, tricking most cancers cells into incorporating defective compounds that halt replication. Folic acid antagonists: Inhibit dihydrofolate reductase, an enzyme required for folate synthesis, thereby blocking off the manufacturing of DNA precursors. instance: Methotrexate. Purine antagonists: Mimic purine bases (adenine and guanine) and get integrated into DNA, disrupting synthesis. example: 6-Mercaptopurine. Pyrimidine antagonists: Mimic pyrimidine bases (cytosine and thymine) to inhibit enzymes like thymidylate synthase or purpose faulty DNA throughout synthesis.[54]

Examples: 5-Fluorouracil and cytarabine: Microtubule-concentrated on marketers those retailers disrupt microtubules, which might be critical for cell division, structure, and delivery. they are divided into two principal categories. Microtubule destabilizers: prevent tubulin from polymerizing into microtubules, arresting cells within the mitotic section.[55]

Examples: Vinca alkaloids like vincristine and vinblastine. Microtubule stabilizers: save you microtubule disassembly with the aid of stabilizing them in a polymerized state, additionally main to mitotic arrest. [56]

Examples: Taxanes like paclitaxel and docetaxel:

Tyrosine kinase inhibitors (TKIs) TKIs are a form of targeted remedy that blocks the signaling pathways of tyrosine kinases, enzymes which can grow to be overactive and power most cancers cell growth thru mutations.[57]

Mechanism: TKIs compete with ATP for binding web sites at the kinase, inhibiting the phosphorylation that is essential for sign transduction. Examples: Imatinib (objectives BCR-ABL in CML) and erlotinib (targets EGFR in lung cancer).[58]

Hormonal remedy: Used for hormone-sensitive cancers like breast and prostate cancer, this remedy blocks the hormones that gasoline tumor growth. Mechanism: it may either reduce the frame's hormone levels or block hormone receptors on cancer cells, stopping growth signals.

Examples: Tamoxifen (blocks estrogen receptors) and aromatase inhibitors (lessen estrogen manufacturing) for breast most cancers, and androgen deprivation therapy for prostate cancer.[59]

Immunotherapy: This approach boosts the frame's very own immune system to fight most cancers. Immune checkpoint inhibitors: Block proteins that generally dampen the immune response (e.g., PD-1, CTLA-4), permitting immune cells to assault cancer more effectively. Examples: Nivolumaband pembrolizumab.[60]

Monoclonal antibodies: Engineered antibodies that bind to precise objectives on cancer cells, marking them for destruction by way of the immune gadget. example: Rituximab (goals CD20) for lymphoma.

Adoptive mobile therapy: Collects and modifies a affected person's very own immune cells (e.g., T-cells) inside the lab to higher understand and attack

 ©IJSRED: All Rights are Reserved

most cancers, then reinfuses them. automobile-T cell therapy is a outstanding type.[61]

3.1. Conventional Chemotherapy: (Cytotoxic agents) traditional cytotoxic chemotherapy retailers goal and kill swiftly dividing cells by way of interfering with their DNA and mobile machinery. these retailers are much less particular than focused treatment plans and affect wholesome, rapid-proliferating cells inclusive of those inside the bone marrow, digestive tract lining, and hair follicles main to not unusual aspect outcomes like myelosuppression, nausea, and hair loss. traditional cytotoxic retailers are widely categorised into the subsequent classes based totally on their mechanism of movement: Alkylating retailers those are chemically reactive capsules that upload alkyl organizations to a cell's DNA, causing harm that inhibits DNA replication and transcription. This ends in programmed cell demise, or apoptosis.[62] Mechanism of action: Non-specific to the mobile cycle, which means they can act on cells at any level. Examples: Nitrogen mustards: Cyclophosphamide and melphalan. Nitrosoureas: Carmustine and lomustine, which could cross the blood-brain barrier. Platinum compounds: Cisplatin, carboplatin, and oxaliplatin, which form crosslinks in DNA. Alkyl sulfonates: Busulfan. 2. Antimetabolites those drugs interfere with DNA and RNA synthesis through mimicking the ordinary constructing blocks of nucleic acids. by way of changing or inhibiting these additives, they halt cellular division.[63] Mechanism of movement: most energetic in the course of the S-segment (DNA synthesis) of the mobile cycle. Examples: Folic acid analogs: Methotrexate. Pyrimidine analogs: five-fluorouracil (five-FU) and capecitabine. Purine analogs: 6-mercaptopurine (6-MP) and 6-thioguanine. three. Antitumor antibiotics unlike antibiotics used for bacterial infections, these retailers paintings by interfering with DNA replication and transcription in cancer cells. Mechanism of action: Varies with the aid of drug.[64] some paintings with the aid of intercalating (placing) into the DNA, even as others produce unfastened radicals that damage DNA. Examples: Anthracyclines: Doxorubicin, daunorubicin, and mitoxantrone. these are acknowledged for capability cardiotoxicity. Others: Bleomycin, dactinomycin, and mitomycin. Microtubule-unfavorable marketers, This class of medication inhibits mitosis (cell department) by means of disrupting the microtubules that form the cellular's structural "scaffolding." they may be often derived from natural plant alkaloids. Mechanism of movement: those agents block the assembly or disassembly of microtubules all through the M-section of the cellular cycle. Examples: Vinca alkaloids: Vincristine, vinblastine, and vinorelbine, which save you the meeting of microtubules.[65] Taxanes: Paclitaxel and docetaxel, which stabilize microtubules and prevent their disassembly.Topoisomerase inhibitors these tablets block the action of topoisomerase enzymes, which are vital for setting apart and unwinding DNA strands at some stage in replication. through inhibiting those enzymes, they motive DNA strand breaks. Mechanism of action: Varies by way of subclass, targeting either topoisomerase I or topoisomerase II, leading to DNA harm. Examples: Topoisomerase I inhibitors: Irinotecan and topotecan.[66] Topoisomerase II inhibitors: Etoposide and teniposide. Miscellaneous marketers: This category includes cytotoxic tablets with precise mechanisms that don't in shape into the opposite groups. Examples: Hydroxyurea: Inhibits the enzyme ribonucleotide reductase, which is needed for DNA synthesis. L-asparaginase: A drug that depletes the amino acid asparagine from the blood, as a few malignant lymphoid cells can not produce sufficient for themselves.[67]

 ©IJSRED: All Rights are Reserved

3.2. Hormonal Therapy: (For breast and prostate cancers)



Hormonal remedy is a form of cancer treatment that alters hormone levels or blocks hormone interest to gradual or stop the growth of sure cancers, in particular breast and prostate cancers. on the grounds that some tumors are hormone-based, concentrated on those hormone pathways is an powerful method. Key mechanisms utilized in hormonal remedy consist of Selective Estrogen Receptor Modulators (SERMs), aromatase inhibitors, and anti-androgens.[68] Mechanisms for breast cancer remedy Selective Estrogen Receptor Modulators (SERMs)

SERMs are medicinal drugs that selectively block or spark off estrogen receptors (ERs) in one-of-a-kind tissues. This provides a dual movement, blockading the estrogenstructured increase of most cancers cells in breast tissue even as appearing like estrogen in different regions, inclusive of bone.[69,70]

Mechanism of action:

SERMs, such as tamoxifen, bind to the estrogen receptor on hormone receptoreffective breast most cancers cells. This binding prevents the frame's very own estrogen from attaching to the receptor and stimulating the cancer cells to grow and multiply. Tamoxifen acts as an estrogen antagonist in breast tissue, which means it blocks estrogen's effects. but, it could act as an estrogen agonist in other tissues, like the uterus and bone. [71]

The specific tissue-selective hobby of SERMs is complex and depends on the specific drug, the estrogen receptor subtype (ERα or ERβ), and the expression of coregulatory proteins in the cellular. Aromatase Inhibitors (AIs) : AIs are a category of medicine that lessen the amount of estrogen within the body through blockading the enzyme aromatase. In postmenopausal girls, who are the number one users of AIs, this enzyme is chargeable for converting androgens into estrogen in fat, muscle, and adrenal gland tissues. Mechanism of motion: AIs block the aromatase enzyme, which catalyzes the final step of estrogen synthesis. This action lowers ordinary estrogen tiers inside the frame, which slows or stops the growth of estrogen receptor-tremendous breast cancers that want estrogen to develop.[72] There are predominant forms of AIs with barely distinctive mechanisms: Non-steroidal AIs (e.g., anastrozole, letrozole) are competitive, reversible inhibitors that bind to the energetic web page of the aromatase enzyme. Steroidal AIs (e.g., exemestane) are irreversible inhibitors, or "inactivators," that completely bind to and deactivate the enzyme. Mechanisms for prostate most cancers remedy. Anti-androgens : Anti-androgens are tablets that block the outcomes of androgens, or male hormones like testosterone. in view that many prostate cancers rely on androgens to develop, blocking off those hormones is a

 ©IJSRED: All Rights are Reserved

important aspect of remedy. Anti-androgens, along with bicalutamide and enzalutamide, paintings in general via binding immediately to the androgen receptor
(AR) inner prostate cancer cells.[73]
by using occupying the receptor, they prevent androgens (more often than not testosterone and dihydrotestosterone) from binding and activating the receptor. This blockade prevents the androgen-receptor complicated from coming into the cellular's nucleus and selling the transcription of genes that guide most cancers cellular boom. [74,75]
more moderen-generation anti-androgens like enzalutamide have a better affinity for the AR and also can inhibit its nuclear translocation and DNA binding. Androgen deprivation therapy (ADT): Anti-androgens are often used as a part of a broader ADT strategy, which may encompass luteinizing hormone-releasing hormone (LHRH) agonists or antagonists to suppress androgen production from the testes. This blended technique is referred to as mixed Androgen Blockade (CAB). [76-78]

4. EFFICACY OF ANTICANCER AGENTS

4.1. Preclinical Efficacy (In Vitro and In Vivo Models):

Preclinical efficacy trying out of anticancer marketers makes use of in vitro (cellularbased) and in vivo (animal-based) fashions to assess a drug's capacity to inhibit cancer boom before human scientific trials. In vitro fashions, such as second and three-D cell cultures, test a compound's direct impact on cancer cells, at the same time as in vivo fashions, including mouse xenografts, examine its consequences on an entire living device. A sequential checking out method, transferring from less complicated in vitro assays to more complex in vivo research, allows pick promising marketers for scientific translation.[79] Preclinical testing techniques In Vitro fashions (cell-primarily based Assays): 2Dmobile Cultures: these are the most primary models where cancer cells are grown as a unmarried layer on a culture dish. they are used to determine a drug's potency and preliminary anti-cancers consequences, regularly measured by using metriclikeIC50values. 3D cell models: advanced models like spheroids and organoids are used to imitate the complicated, 3-dimensional structure of human tumors more carefully than 2nd cultures. those models better constitute tumor structur e, heterogeneity, and the extracellular matrix, offering a extra realistic platform for drug screeningand customized medicine. InVivo models (Animal-based studies): Xenografts: A common in vivo model in which human most cancers cells are implanted into immunocompromised mice. those models permit researchers to take a look at a drug's efficacy, pharmacokinetics, and toxicity within a complex dwelling organism. affected person-Derived fashions: research are more and more using affected personderived tumors to create extra relevant models that higher reflect person patient wishes and the complexity of human cancers. cause and barriers motive: these preclinical models are crucial for selecting and prioritizing drug candidates with a excessive capability for clinical success. limitations: no matter their utility, preclinical models frequently fail to accurately are expecting medical efficacy, as evidenced by means of the high failure charge of medication in scientific trials. This disparity is attributed to the restrictions of the fashions themselves, inclusive of the complexity of cancer and the differences between in vitro and in vivo environments.[80]

4.1 Toxicity and Side Effects:

Unique forms of cancer therapies have distinct mechanisms and, as a result, one of a kind toxicity profiles and side consequences. The side results rise up because the remedies, at the same time as focused on most cancers cells, also effect healthful cells and systems in the frame.
Cytotoxic chemotherapy: This traditional cancer remedy works by attacking rapidly dividing cells. even as this correctly kills cancer cells, it also harms wholesome, fast-dividing cells like those within the bone marrow, hair follicles, and digestive tract. commonplace side consequences. Myelosuppression: A lower in bone marrow activity, leading to lower manufacturing of pink blood cells, white blood cells, and platelets. this could purpose anemia, an expanded threat of infection, and easy bruising or bleeding.[81]
Nausea and vomiting: those are commonplace due to the effect of chemotherapy at the cells lining the digestive tract. Fatigue: Feeling continuously tired is a customary facet effect. Hair loss: A aspect impact that takes place because chemotherapy impacts the cells in hair follicles. Mucositis: inflammation and ulceration of the

 ©IJSRED: All Rights are Reserved

mucous membranes, particularly inside the mouth and gut. Sterility and infertility: harm to reproductive cells can cause these troubles. focused remedy centered treatment options interfere with unique molecules concerned in most cancers cellular increase and survival, making them generally much less poisonous than traditional chemotherapy. however, they are no longer with out side consequences, which vary depending on the unique "goal". commonplace facet outcomes: skin rash: Many focused healing procedures, especially those who inhibit signaling pathways, can motive pores and skin rashes. hypertension (excessive blood stress): a few targeted treatment plans can affect blood vessels, main to high blood pressure.

Fluid retention: Swelling and weight gain can arise from fluid build-up. Gastrointestinal issues:focused therapy can nevertheless cause diarrhea, constipation, or mouth sores.

Hepatitis: infection of the liver.[82]

Immunotherapy : This treatment stimulates the body's personal immune device to combat cancer. The facet consequences, called immuneassociated destructive events (irAEs), result from the activated immune gadget attacking wholesome tissues. not unusual immune-related adverse activities (irAEs): Colitis: The immune device can assault the colon, causing inflammation, diarrhea, and abdominal ache. Pneumonitis: The immune machine can assault the lungs, inflicting inflammation that could cause shortness of breath or cough. Dermatologic toxicity (pores and skin rash): Rashes and itching are a number of the maximum common irAEs. Endocrine toxicities: The immune machine can assault endocrine organs, inflicting conditions like thyroiditis (thyroid irritation) or hypophysitis (pituitary gland infection). [83]

Hepatitis: The liver is a ability goal for immune-associated inflammation. Fatigue: a completely common, non-particular aspect effect.[84]

4.2 Challenges in Drug Delivery: Poor bioavailability, instability, lack of tumorspecific targeting leading to off-site effects.

Manage the spinned words as you want... Drug shipping faces numerous key challenges which can undermine healing efficacy and purpose damage through affecting wholesome tissues.[85-88] Bioavailability: Bioavailability is the fraction of an administered drug that reaches the systemic circulation. while a drug has terrible bioavailability, a big dose may be required, which could boom the hazard of detrimental side effects and toxicity. Physicochemical boundaries Low solubility: Many new drug applicants, particularly small-molecule drugs, have low aqueous solubility, making it hard for the body to take in them. terrible permeability: tablets must cross biological membranes, together with the epithelial cells of the gastrointestinal tract, to reach the bloodstream. poor permeability can limit absorption.[89-92] Chemical properties: the steadiness, lipophilicity, and molecular size of a drug all influence its ability to pass through biological membranes. organic limitations.[92-95] Metabolism: For orally administered pills, the "first-skip impact" inside the liver can extensively lessen the attention of lively drug that reaches the bloodstream. Enzymes in the intestine can also degrade capsules before they are absorbed. Efflux transporters: Proteins like P-glycoprotein (P-gp) within the intestinal lining can actively pump drugs out of the cells and lower back into the gastrointestinal tract, restricting their absorption.Intestine microbiome: The community of microbes within the intestine can alter a drug's metabolism and absorption, doubtlessly changing its bioavailability.[96] Instability tablets can lose their potency or become poisonous because of bodily and chemical instability.[97]

Chemical instability: This occurs when a drug degrades because of chemical reactions, which include hydrolysis, oxidation, or reduction. bodily instability: This includes adjustments inside the drug's bodily houses, like its crystalline structure, which could modify its dissolution price and affect bioavailability. Environmental degradation: Environmental elements like temperature, humidity, oxygen, and light can accelerate degradation.[98]

Biomolecule degradation: For organic capsules, consisting of proteins and peptides, organic fluids and enzymes inside the frame can degrade them earlier than they reach their target. loss of tumor-unique focused on conventional chemotherapies regularly rely on the systemic administration of cytotoxic pills that cannot distinguish between wholesome and cancerous cells. This loss of focused on leads to

 ©IJSRED: All Rights are Reserved

off-website online results and boundaries remedy effectiveness. Systemic toxicity: Chemotherapy capsules distribute at some point of the frame, inflicting intense aspect effects by using unfavourable healthy cells with excessive boom fees, consisting of bone marrow, hair follicles, and the gastrointestinal tract. [99] Non-particular accumulation: Low-molecular-weight chemotherapy drugs tend to accumulate on the periphery of tumors and are frequently cleared from the body earlier than they could reach the tumor middle. Drug resistance: The systemic management of medicine can cause the development of a couple of drug resistance mechanisms within the tumor cells through the years, contributing to remedy failure. complicated tumor microenvironment: The shipping of therapeutics is hindered via the dense extracellular matrix, excessive interstitial fluid pressure, and heterogeneous blood vessel community within tumors. Overcoming challenges with novel drug delivery structures New techniques, especially the ones using nanotechnology, are being evolved to cope with these problems.

Nanocarriers: structures like nanoparticles, liposomes, and micelles can encapsulate capsules to decorate their solubility, enhance stability, and shield them from degradation. targeted transport: Nanocarriers can be functionalized with specific ligands or antibodies that understand receptors overexpressed on cancer cells. This "active targeting" promotes selective uptake with the aid of tumor cells. enhanced permeability and retention (EPR) impact: In "passive concentrated on," nanocarriers exploit the leaky and disorganized blood vessels not unusual in tumors to preferentially accumulate at the disorder site. Stimuli-responsive launch: clever nanocarriers can be engineered to launch their payload in reaction to inner tumor-specific stimuli (e.g., low pH, excessive enzyme stages) or external triggers (e.g., light, warmness).[00]

CONCLUSION

Cancer continues to present an overwhelming global health challenge due to its complex pathophysiology, high mortality, and significant socioeconomic impact. Over the past decades, anticancer research has evolved remarkably, transitioning from conventional cytotoxic chemotherapy towards more refined and selective strategies. This systematic review highlights how molecular insights have reshaped drug discovery, enabling the development of targeted therapies and immunotherapeutic approaches that offer improved outcomes and reduced systemic toxicity. Traditional chemotherapeutic classes, including alkylating agents, antimetabolites, and microtubule inhibitors, still serve as foundational treatments; however, their non-selective nature often results in adverse effects and therapeutic limitations The emergence of targeted therapies such as tyrosine kinase inhibitors, monoclonal antibodies, hormonal agents, and immune checkpoint inhibitors represents a paradigm shift in oncology. These modalities exploit specific vulnerabilities within cancer cells, providing personalized treatment opportunities and enabling precision medicine. Immunotherapy, in particular, has demonstrated durable responses in malignancies once considered refractory, though challenges such as immune-related toxicities and acquired resistance persist. Preclinical and clinical evaluation models continue to advance, incorporating three-dimensional tumor models, patient-derived xenografts, and biomarker-driven trial designs to enhance translational value. Despite progress, significant barriers remain. Drug resistance, tumor heterogeneity, poor bioavailability, and inadequate tumor-specific delivery hinder therapeutic success. Innovative drug delivery systems, especially nanotechnology-based carriers, show promise in overcoming these obstacles by improving stability, targeted accumulation, and controlled release. Furthermore, integrating artificial intelligence, multi-omics analytics, and systems biology is accelerating lead discovery and optimizing combination regimens.

REFERENCE

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):7–33.
4.Vogelstein B, Kinzler KW. The genetic basis of human cancer. Cold Spring Harb Perspect Biol. 2013;5(1):a008652.

 ©IJSRED: All Rights are Reserved

5.Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discover. 2022;12(1):31–46.
6.Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
7.Kunkel TA. Cellular DNA repair and mutagenesis. Oncogene. 2004;23(11):1879– 1891.
8.Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
9.Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
10.DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653.
11.Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661.
12.Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 30 years. J Nat Prod. 2020;83(3):770–803.
13.Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol. J Am Chem Soc. 1971;93(9):2325–2327.
14.Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing anticancer agents. Chem Rev. 2009;109(7):3012–3043.
15.Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005;4(3):206–220.
16.Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14(2):111–129.
17.Cragg GM, Kingston DGI, Newman DJ, editors. Anticancer agents from natural products. Boca Raton: CRC Press; 2012.
18.Newman DJ, Cragg GM. Natural products in drug discovery and development. Pharm Biol. 2012;50(4):428–438.
19.Li JWH, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science. 2009;325(5937):161–165.
20.Mayer AMS, Glaser KB, Cuevas C, et al. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci. 2010;31(6):255–265.
21.Shaik BB, Katari NK, Jonnalagadda SB. Role of natural products in developing novel anticancer agents: a perspective. Chem Biodivers. 2022;19(11):e202200535.
22.Shakya AK, Naik RR. The chemotherapeutic potentials of compounds isolated from plant, marine, fungus, and microorganism: mechanisms and prospects. J Trop Med. 2022;2022:5919453.
23.Li Y, Zhang T, Kloos RT. Flavonoids and anticancer activities: mechanisms and prospects. Pharmacol Res. 2021;163:105255.
24.Pan L, Gong Y, Lu J. Marine natural products as leads for anticancer agents: an updated review. Mar Drugs. 2023;21(4):203.
25.Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, et al. Anticancer drug discovery based on natural products: from computational approaches to clinical studies. Biomedicines. 2024;12(1):201.
26. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
27.Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
28.Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982.
29.Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
30.Ribas A, Wolchok JD. Combining cancer immunotherapy: a new era. Science. 2018;359(6382):1350–1355.
31.Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
32.Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
33.Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–330.
34.Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.

 ©IJSRED: All Rights are Reserved

35.Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
36.Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736.
37.June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
38.June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.
39.Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.
40.Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
41.Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
42.Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
43.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel in refractory large Bcell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
44.Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
45.Locke FL, Ghobadi A, Jacobson CA, et al. Long-term outcomes of axicabtagene ciloleucel in refractory large B-cell lymphoma. Lancet Oncol. 2019;20(1):31–42.
46.Gill S, June CH. Going viral: CAR-T cells and beyond. Cancer Discov. 2015;5(8):866– 868.
47.Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors:
challenges and opportunities. Front Immunol. 2017;8:230.
48.Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031– 1037.
49.Sawyers CL. Targeted cancer therapy. Nature. 2004;432(7015):294–297.
50.Cohen MH, Williams GA, Sridhara R, Pazdur R. FDA drug approval summaries: small molecule targeted agents. Oncologist. 2007;12(3):333–338.
51.Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
52.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
53.Hyman DM, et al. Targeted therapy for molecularly defined subsets of cancer. Nat Rev Clin Oncol. 2017;14(9):561–577.
54.Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy of bevacizumab in metastatic breast cancer. N Engl J Med. 2004;350(8):724–732.
55.Gainor JF, Shaw AT. Resistance mechanisms to targeted therapies in ALK- and EGFRdriven cancers. Nat Rev Clin Oncol. 2016;13(12):1–14.
56.Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: an analysis of FDAapproved drugs. Drug Discov Today. 2015;20(11):1236–1244.
57.Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
58.Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells. Nature. 2005;434(7035):917–921.
59.Helleday T. The underlying mechanism for PARP and BRCA synthetic lethality. Mol Oncol. 2011;5(4):387–393.
60.O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–560.
61.Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinumsensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
62.Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. Lancet Oncol. 2012;13(4):340–349.
63.Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–1512.
64.O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–430.

 ©IJSRED: All Rights are Reserved

65.Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
66.Whittaker SR, Marais R. Targeting the cell cycle in cancer: new therapeutic approaches. Br J Cancer. 2013;108(2):248–252.
67.Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166.
68.Fry DW. Development of inhibitors of Aurora kinases and mitotic kinases. Cancer Lett. 2012;316(1):8–18.
69.Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257.
70.Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol.
2007;35(4):495–516.
71.Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–741.
72.White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–410.
73.Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019;9(9):1167–1181.
74.Fulda S. Targeting apoptosis for anticancer therapy. Semin Cancer Biol. 2015;31:84–
88.
75.Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
76.Ferrara N, Hillan KJ, Novotny W. Discovery and development of bevacizumab, an antiVEGF antibody. Nat Rev Drug Discov. 2004;3(5):391–400.
77.Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257.
78.Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–2049.
79.Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.
2004;350(23):2335–2342.
80.Ellis LM, Hicklin DJ. VEGF pathway: resistance mechanisms and combination strategies. Clin Cancer Res. 2008;14(16):5244–5249.
81.Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031– 1037.
82.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
83.Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
84.Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
85.Van Cutsem E, Peeters M, Siena S, et al. Cetuximab in metastatic colorectal cancer:
key trials and outcomes. Lancet. 2009;374(9696):1536–1544.
86.Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
87.Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
88.Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
89.Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37.
90.McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628.
91.Turajlic S, Swanton C. Metastasis as a form of clonal evolution. Cancer Cell. 2016;29(5):624–636.
92.Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
93.Zubov D, et al. Artificial intelligence and machine learning in cancer drug discovery: a review. Nat Rev Drug Discov. 2021;20(9):659–681.
94.Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration for precision oncology. Brief Bioinform. 2020;21(4):1001–1016.

 ©IJSRED: All Rights are Reserved

95.Ekins S, Williams AJ. In silico methods for drug repurposing and discovery. Trends Pharmacol Sci. 2010;31(8):350–358.
96.Li J, Lenferink AE, Deng Y, et al. Prediction of drug combinations by network pharmacology. Bioinformatics. 2015;31(12):i47–i56.
97.Waller C, et al. Systems biology approaches for anticancer drug discovery. Mol Syst Biol. 2016;12(4):879.
98.Ledford H. Translational cancer research: from bench to bedside — challenges and roadblocks. Nature. 2011;471(7339):S14–S15.
99.Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
100. Elsori D, Pandey P, Verma M, et al. Recent advancement in the anticancer efficacy of the natural flavonoid scutellarin: a comprehensive review. Front Pharmacol. 2025;16:1579609.

 ©IJSRED: All Rights are Reserved